Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study.
Identifieur interne : 000A65 ( Ncbi/Merge ); précédent : 000A64; suivant : 000A66Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study.
Auteurs : Rajesh Pahwa [États-Unis] ; Kelly E. LyonsSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2003.
English descriptors
- KwdEn :
- Aged, Antidepressive Agents, Tricyclic (administration & dosage), Antidepressive Agents, Tricyclic (pharmacology), Antidepressive Agents, Tricyclic (therapeutic use), Cross-Over Studies, Double-Blind Method, Essential Tremor (diagnosis), Essential Tremor (drug therapy), Female, Humans, Male, Mianserin (administration & dosage), Mianserin (analogs & derivatives), Mianserin (pharmacology), Mianserin (therapeutic use), Outcome Assessment (Health Care), Psychomotor Performance (drug effects), Questionnaires, Severity of Illness Index.
- MESH :
- chemical , administration & dosage : Antidepressive Agents, Tricyclic, Mianserin.
- chemical , analogs & derivatives : Mianserin.
- chemical , pharmacology : Antidepressive Agents, Tricyclic, Mianserin.
- chemical , therapeutic use : Antidepressive Agents, Tricyclic, Mianserin.
- diagnosis : Essential Tremor.
- drug effects : Psychomotor Performance.
- drug therapy : Essential Tremor.
- Aged, Cross-Over Studies, Double-Blind Method, Female, Humans, Male, Outcome Assessment (Health Care), Questionnaires, Severity of Illness Index.
Abstract
We sought to determine whether mirtazapine is safe and well-tolerated as a treatment for essential tremor (ET). We studied mirtazapine in a randomized, double-blind, placebo-controlled, crossover study of 17 ET patients. Patients were started with 15 mg per day of either mirtazapine or placebo for 1 week and the dose was escalated weekly until the targeted dose of 45 mg per day was achieved. This dose was maintained for 2 weeks. Tremor was assessed at baseline and after 14 days of 45 mg of mirtazapine or placebo. There was a minimum washout period of 14 days between the two arms of the study. Tremor assessments included global improvement, Fahn Tolosa Marin Tremor Rating Scale, Beck Depression Inventory and the Parkinson's Disease Questionnaire-39. Patient global improvement ratings indicated that in the placebo condition 12 patients were unchanged and 1 patient was mildly improved. In the mirtazapine condition, 10 patients were unchanged, 2 were moderately improved and 1 was markedly improved. There was no significant improvement with mirtazapine or placebo compared to baseline as measured by the Tremor Rating Scale. Adverse effects were more common in the mirtazapine group and included drowsiness, confusion, dry mouth, weight gain, polyuria, itching, nausea, gait and balance problems, blurred vision, and bad taste. We conclude that the majority of the ET patients do not benefit from mirtazapine. Mirtazapine has significant adverse effects and should be used cautiously in ET patients.
DOI: 10.1002/mds.10371
PubMed: 12722174
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003786
- to stream PubMed, to step Curation: 003786
- to stream PubMed, to step Checkpoint: 003731
Links to Exploration step
pubmed:12722174Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study.</title>
<author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA. rpahwa@kumc.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</wicri:regionArea>
<placeName><region type="state">Kansas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E" last="Lyons">Kelly E. Lyons</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:12722174</idno>
<idno type="pmid">12722174</idno>
<idno type="doi">10.1002/mds.10371</idno>
<idno type="wicri:Area/PubMed/Corpus">003786</idno>
<idno type="wicri:Area/PubMed/Curation">003786</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003731</idno>
<idno type="wicri:Area/Ncbi/Merge">000A65</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study.</title>
<author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA. rpahwa@kumc.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</wicri:regionArea>
<placeName><region type="state">Kansas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E" last="Lyons">Kelly E. Lyons</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antidepressive Agents, Tricyclic (administration & dosage)</term>
<term>Antidepressive Agents, Tricyclic (pharmacology)</term>
<term>Antidepressive Agents, Tricyclic (therapeutic use)</term>
<term>Cross-Over Studies</term>
<term>Double-Blind Method</term>
<term>Essential Tremor (diagnosis)</term>
<term>Essential Tremor (drug therapy)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Mianserin (administration & dosage)</term>
<term>Mianserin (analogs & derivatives)</term>
<term>Mianserin (pharmacology)</term>
<term>Mianserin (therapeutic use)</term>
<term>Outcome Assessment (Health Care)</term>
<term>Psychomotor Performance (drug effects)</term>
<term>Questionnaires</term>
<term>Severity of Illness Index</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antidepressive Agents, Tricyclic</term>
<term>Mianserin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Mianserin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antidepressive Agents, Tricyclic</term>
<term>Mianserin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antidepressive Agents, Tricyclic</term>
<term>Mianserin</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Essential Tremor</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Psychomotor Performance</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Essential Tremor</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Cross-Over Studies</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Outcome Assessment (Health Care)</term>
<term>Questionnaires</term>
<term>Severity of Illness Index</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We sought to determine whether mirtazapine is safe and well-tolerated as a treatment for essential tremor (ET). We studied mirtazapine in a randomized, double-blind, placebo-controlled, crossover study of 17 ET patients. Patients were started with 15 mg per day of either mirtazapine or placebo for 1 week and the dose was escalated weekly until the targeted dose of 45 mg per day was achieved. This dose was maintained for 2 weeks. Tremor was assessed at baseline and after 14 days of 45 mg of mirtazapine or placebo. There was a minimum washout period of 14 days between the two arms of the study. Tremor assessments included global improvement, Fahn Tolosa Marin Tremor Rating Scale, Beck Depression Inventory and the Parkinson's Disease Questionnaire-39. Patient global improvement ratings indicated that in the placebo condition 12 patients were unchanged and 1 patient was mildly improved. In the mirtazapine condition, 10 patients were unchanged, 2 were moderately improved and 1 was markedly improved. There was no significant improvement with mirtazapine or placebo compared to baseline as measured by the Tremor Rating Scale. Adverse effects were more common in the mirtazapine group and included drowsiness, confusion, dry mouth, weight gain, polyuria, itching, nausea, gait and balance problems, blurred vision, and bad taste. We conclude that the majority of the ET patients do not benefit from mirtazapine. Mirtazapine has significant adverse effects and should be used cautiously in ET patients.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">12722174</PMID>
<DateCreated><Year>2003</Year>
<Month>04</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted><Year>2003</Year>
<Month>09</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised><Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>18</Volume>
<Issue>5</Issue>
<PubDate><Year>2003</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study.</ArticleTitle>
<Pagination><MedlinePgn>584-7</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We sought to determine whether mirtazapine is safe and well-tolerated as a treatment for essential tremor (ET). We studied mirtazapine in a randomized, double-blind, placebo-controlled, crossover study of 17 ET patients. Patients were started with 15 mg per day of either mirtazapine or placebo for 1 week and the dose was escalated weekly until the targeted dose of 45 mg per day was achieved. This dose was maintained for 2 weeks. Tremor was assessed at baseline and after 14 days of 45 mg of mirtazapine or placebo. There was a minimum washout period of 14 days between the two arms of the study. Tremor assessments included global improvement, Fahn Tolosa Marin Tremor Rating Scale, Beck Depression Inventory and the Parkinson's Disease Questionnaire-39. Patient global improvement ratings indicated that in the placebo condition 12 patients were unchanged and 1 patient was mildly improved. In the mirtazapine condition, 10 patients were unchanged, 2 were moderately improved and 1 was markedly improved. There was no significant improvement with mirtazapine or placebo compared to baseline as measured by the Tremor Rating Scale. Adverse effects were more common in the mirtazapine group and included drowsiness, confusion, dry mouth, weight gain, polyuria, itching, nausea, gait and balance problems, blurred vision, and bad taste. We conclude that the majority of the ET patients do not benefit from mirtazapine. Mirtazapine has significant adverse effects and should be used cautiously in ET patients.</AbstractText>
<CopyrightInformation>Copyright 2003 Movement Disorder Society</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pahwa</LastName>
<ForeName>Rajesh</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA. rpahwa@kumc.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lyons</LastName>
<ForeName>Kelly E</ForeName>
<Initials>KE</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000929">Antidepressive Agents, Tricyclic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>250PJI13LM</RegistryNumber>
<NameOfSubstance UI="D008803">Mianserin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>A051Q2099Q</RegistryNumber>
<NameOfSubstance UI="C035133">mirtazapine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000929">Antidepressive Agents, Tricyclic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018592">Cross-Over Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D020329">Essential Tremor</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008803">Mianserin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs & derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D017063">Outcome Assessment (Health Care)</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011597">Psychomotor Performance</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year>
<Month>5</Month>
<Day>2</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2003</Year>
<Month>9</Month>
<Day>18</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2003</Year>
<Month>5</Month>
<Day>2</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">12722174</ArticleId>
<ArticleId IdType="doi">10.1002/mds.10371</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Kansas</li>
</region>
</list>
<tree><noCountry><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E" last="Lyons">Kelly E. Lyons</name>
</noCountry>
<country name="États-Unis"><region name="Kansas"><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A65 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000A65 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:12722174 |texte= Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:12722174" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |